Maze Therapeutics, Inc. MAZE
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -21.72%
- 1 year
- -8.75%
5D -0.57 (-1.65%)
- Market cap
- 1.77B
- Revenue (ttm)
- 20.00M
- EPS (ttm)
- -2.62
- Shares out
- 54.68M
- Forward P/E
- -9.76
- YTD return
- -21.72%
- 1-year return
- -8.75%
- 50-day average
- 29.10
- 200-day average
- 31.16
- Volume
- 1.00M
- Avg volume
- 716.97K
- Open
- 31.20
- Previous close
- 31.20
- Day's range
- 30.69 – 32.74
- 52-week range
- 21.95 – 53.65
- Analysts
- Strong Buy
- Price target
- 62.46 (+92.6%)
- Earnings date
- Mar 24, 2027
Key statistics
- Enterprise value
- 1.38B
- Price / sales
- 88.67
- Price / book
- 4.27
- Free cash flow
- -68.62M
- Total cash
- 389.66M
- Total debt
- 59.64M
- Return on equity
- -37.49%
- Short % of float
- 14.01%
Fundamental scorecard
4 of 25 checks passed on MAZE’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 46.00
- Target (mean)
- 62.46
- Target (high)
- 110.00
- Strong buy1
- Buy13
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 24, 2027
Expected Mar 24, 2027. Consensus EPS estimate -0.7518.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 24, 2027 | Dec 30, 2026 | -0.85 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.75939 | -0.79 | -0.03 | -4.03% |
| Aug 12, 2026 | Jun 30, 2026 | -0.71731 | -0.76 | -0.04 | -5.95% |
| May 12, 2026 | Mar 31, 2026 | -0.43 | -0.45 | -0.02 | -4.65% |
| Mar 25, 2026 | Dec 31, 2025 | -0.73 | -0.65 | +0.08 | +10.96% |
| Nov 6, 2025 | Sep 30, 2025 | -0.74 | -0.66 | +0.08 | +10.81% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 10, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 19, 2026 | Canaccord Genuity | init | — | Buy |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Sep 23, 2026 | Wedbush | reit | Outperform | Outperform |
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mazetx.com
News
Maze Therapeutics: Vertex Is Building The Road, And Maze Gets To Drive On It JP Morgan Maintains Overweight on Maze Therapeutics, Lowers Price Target to $51
Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $49
Maze Therapeutics Q3 EPS $(0.79) Misses $(0.77) Estimate
Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75
Your note
Sign in to keep a note on MAZE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BACHRODT AMY | Officer | Sale | Mar 31, 2026 | 12,965 |
| BERNSTEIN HAROLD | Officer | Sale | Sep 3, 2026 | 0 |
| COLOMA JASON V PH.D. | Chief Executive Officer | Sale | Nov 1, 2026 | 0 |
| COURTNEY PHILLIPS | General Counsel | Sale | Sep 2, 2026 | 7,007 |
| DANDEKAR ATUL | Officer | Sale | Sep 28, 2026 | 32,316 |
| HOMCY CHARLES J | Director | Stock Gift | May 3, 2026 | 31,113 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 9.66% | 5,282,915 | 171.32M | Sep 29, 2026 |
| Arch Venture Management, Llc | 7.53% | 4,120,053 | 133.61M | Sep 29, 2026 |
| Deep Track Capital, Lp | 7.47% | 4,083,969 | 132.44M | Sep 29, 2026 |
| TRV GP IV, LLC | 6.81% | 3,723,958 | 120.77M | Sep 29, 2026 |
| Blackrock Inc. | 6.79% | 3,712,670 | 120.40M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 6.23% | 3,408,045 | 110.52M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.58% | 1,411,990 | 45.79M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.79% | 978,329 | 31.73M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.67% | 913,802 | 29.63M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.43% | 779,781 | 25.29M | Sep 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 0.77% | 421,350 | 13.66M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.71% | 386,845 | 12.55M | Aug 30, 2026 |
